The Molbio Diagnostics IPO is attracting investor attention as the healthcare and diagnostics company enters the primary market. The company has fixed a price band of ₹768 to ₹807 per share, while brokerage firm Geojit Research has assigned a “Subscribe” rating to the public issue.
According to Geojit Research, Molbio Diagnostics has an established position in India's molecular diagnostics market, supported by its Truenat platform, a scalable business model and strong revenue growth.
However, the IPO also carries certain risks, including the company's high dependence on government contracts and the concentration of revenue from tuberculosis (TB) diagnostic products.
Molbio Diagnostics IPO Dates and Price Band
The Molbio Diagnostics IPO will open for subscription on August 10, 2026, and close on August 12, 2026.
The company has fixed the IPO price band at ₹768–₹807 per share.
The issue size is approximately ₹939.9 crore, comprising a fresh issue of around ₹200.2 crore and an Offer for Sale (OFS) of approximately ₹739.7 crore.
The shares are proposed to be listed on both the BSE and NSE.
Molbio Diagnostics IPO: Retail Investment
The minimum lot size for retail investors is 18 shares.
At the upper end of the price band, investors will need approximately ₹14,526 to subscribe to one lot.
IPO Detail Information
IPO Opening Date August 10, 2026
IPO Closing Date August 12, 2026
Price Band ₹768–₹807
Issue Size Approx. ₹939.9 crore
Fresh Issue Approx. ₹200.2 crore
OFS Approx. ₹739.7 crore
Lot Size 18 shares
Retail Investment ₹14,526 at upper price band
Listing BSE, NSE
What Does Molbio Diagnostics Do?
Established in 2000, Molbio Diagnostics operates in the molecular diagnostics segment and develops point-of-care testing solutions for infectious and non-infectious diseases.
Its flagship Truenat platform is a portable, battery-operated molecular diagnostic system designed to provide test results within approximately one hour.
The portable nature of the platform is particularly relevant for healthcare settings where access to large laboratory infrastructure can be limited.
Molbio Diagnostics Financial Performance
According to the Geojit Research report cited in the analysis, Molbio Diagnostics has recorded strong revenue growth in recent years.
Between FY2024 and FY2026, the company recorded a reported 32% CAGR in revenue, while profit after tax (PAT) grew at a CAGR of approximately 11%.
The financial performance is one of the key factors supporting Geojit's positive view of the IPO.
The brokerage believes Molbio's established position in molecular diagnostics and its scalable business model could support further growth over the medium to long term.
How Will Molbio Use IPO Funds?
A portion of the fresh issue proceeds will be directed towards strengthening Molbio Diagnostics' research and manufacturing capabilities.
The company plans to allocate approximately:
₹125 crore towards a research and development facility.
₹81 crore towards the purchase of plant and machinery.
The remaining proceeds towards general corporate purposes.
Investment in R&D and machinery could help the company expand its product capabilities and manufacturing capacity.
Why Has Geojit Given a ‘Subscribe’ Rating?
Geojit Research has assigned a “Subscribe” rating to the Molbio Diagnostics IPO.
According to the brokerage, the company benefits from its strong position in the molecular diagnostics segment, an established product platform and a business model that can be scaled across markets.
The brokerage also points to the expected growth of the diagnostics industry as a potential long-term growth driver.
Geojit estimates that the diagnostics market could grow by approximately 12%, creating a favourable backdrop for companies operating in the sector.
Based on these factors, Geojit considers Molbio Diagnostics an attractive proposition for medium- to long-term investors.
Molbio Diagnostics IPO Risks
Despite the positive outlook, investors should also consider the risks highlighted by the brokerage.
1. High Government Dependency
One of the biggest risks is Molbio Diagnostics' dependence on government bodies and aid agencies.
According to the report, approximately 85% of the company's revenue comes from contracts with government bodies and aid agencies.
Such dependence means changes in government procurement policies, tender processes, healthcare programmes or public spending could potentially affect the company's revenue.
2. High Product Concentration
Another key concern is the concentration of revenue around TB diagnostics.
Approximately 70% of Molbio Diagnostics' total revenue comes from TB diagnostic kits, according to the report.
This creates concentration risk because a substantial portion of the company's business depends on one therapeutic and diagnostic area.
Expansion into additional diagnostic categories could therefore be important for reducing this concentration over time.
Molbio Diagnostics IPO: Investment View
The IPO offers investors exposure to India's growing diagnostics and healthcare sector through a company with an established molecular diagnostics platform.
The Truenat system, strong revenue growth and planned investment in R&D and manufacturing capacity are among the key positives.
At the same time, investors need to carefully evaluate the company's government dependency and product concentration before making an investment decision.
Geojit Research has taken a positive view and assigned a “Subscribe” rating, particularly from a medium- to long-term perspective.
However, a brokerage recommendation is not a guarantee of listing gains or future returns, and investors should evaluate the IPO based on their own risk profile and investment objectives.
Molbio Diagnostics IPO: Key Pros and Cons
Positives
Established presence in molecular diagnostics.
Flagship Truenat point-of-care molecular testing platform.
Strong revenue growth between FY2024 and FY2026.
Planned investment in R&D and manufacturing.
Exposure to the expanding diagnostics market.
Geojit Research has given a “Subscribe” rating.
Risks
Around 85% revenue dependence on government bodies and aid agencies.
Around 70% revenue concentration in TB diagnostic kits.
IPO includes a substantial OFS component.
Brokerage recommendations and market conditions can change.
Molbio Diagnostics IPO: Should You Subscribe?
Based on the Geojit Research report cited in this analysis, the brokerage has recommended subscribing to the Molbio Diagnostics IPO.
The company's molecular diagnostics portfolio, Truenat platform, historical revenue growth and exposure to a growing healthcare market are key positives.
However, investors should not ignore the high dependence on government contracts and the concentration of revenue in TB diagnostics.
For investors with a medium- to long-term horizon, Geojit's view suggests the IPO could be worth considering. Investors should nevertheless review the company's IPO documents, valuation, financial performance and risk factors before making an investment decision.
Former India cricketer Ajinkya Rahane has urged caution over discussions surrounding 15-year-old
The Centre has clarified its position on the proposed changes related to UPI transactions, with U
India’s Crude Oil Imports Hit Record High Again in July Despite Western Sanctions
India's reliance on Russian crude oil remained strong in July, with imports staying close to reco
RBI ₹10, ₹20 Plastic Notes: When Will Polymer Currency Hit the Market? Governor Gives Big Update
The Reserve Bank of India (RBI) is moving ahead with plans to introduce polymer (plastic) banknot
Telegram Removed From Apple App Store, Returns Shortly After; Here's Know What Happened
Telegram was temporarily removed from the Apple App Store on Monday, August 3, leaving users in s
Moto G Max Launch on August 14: Motorola Brings 7000mAh Battery, 50MP Sony Camera
Motorola is expanding its popular Moto G smartphone lineup in India with a new model, the Moto G
WhatsApp Account Recovery: Account Suddenly Under Review? Know How to Restore Access
A large number of WhatsApp users across the world, including users in India, suddenly found their
Dabur vs FSSAI: Company Alleges Discrimination, Says ₹150 Crore Stock Was at Risk
FMCG major Dabur has moved the Delhi High Court against the Food Safety and Standards Authority o
The Reserve Bank of India (RBI) has kept the repo rate unchanged at 5.25%, providing no immediate
Babar Azam was dismissed for 88 on Tuesday, ending his hopes of scoring his first Test century si
